Study of Mutations in Ovarian Cancer
Author Information
Author(s): Matulonis Ursula A., Hirsch Michelle, Palescandolo Emanuele, Kim Eejung, Liu Joyce, van Hummelen Paul, MacConaill Laura, Drapkin Ronny, Hahn William C.
Primary Institution: Dana-Farber Cancer Institute
Hypothesis
The study aims to determine the frequency and types of point somatic mutations in high grade serous ovarian cancer (HGSC).
Conclusion
The study found that 56% of tumor samples harbored candidate mutations, indicating that screening for somatic mutations may lead to new therapies for ovarian cancer patients.
Supporting Evidence
- 56% of tumor samples had candidate mutations.
- The most common mutations were found in genes like EGFR, KRAS, and TP53.
- The study suggests that identifying these mutations could lead to new treatment options.
Takeaway
The researchers looked at cancer samples to find changes in genes that could help doctors treat ovarian cancer better.
Methodology
The study used a mutation detection protocol called OncoMap to analyze DNA from formalin-fixed paraffin-embedded tissue samples.
Limitations
Only 'hotspot' mutations were detected, and validation of mutations is necessary; other mutations not included in the OncoMap panel may be missed.
Participant Demographics
Patients with advanced staged HGSC ovarian cancer were selected, excluding those with known BRCA germline mutations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website